MedTrace Logo

Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent

NCT05230940 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-05-28

No results posted yet for this study

Summary

This study is a multi-center, randomized, national, observer-blinded, active-controlled phase IIB clinical trial to determine the efficacy, immunogenicity, and safety of two-doses of inactive COVID-19 vaccine (TURKOVAC) vaccine versus the two-doses CoronaVac (Sinovac) vaccine in healthy adolescents aged 12-18 years.

Conditions

Interventions

BIOLOGICAL

TURKOVAC

Inactive COVID-19 Vaccine - TURKOVAC

BIOLOGICAL

CoronaVac

It has 600 subunit of SARS-CoV-2 virus antigen

Sponsors & Collaborators

  • Health Institutes of Turkey

    lead OTHER_GOV

Principal Investigators

  • Aslınur Özkaya Parlakay, Prof. · Faculty Member

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-18
Primary Completion
2023-05-15
Completion
2024-02-08

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05230940 on ClinicalTrials.gov